NESINA

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Hong Kong SAR China, Japan, Singapore.

Active ingredients

The drug NESINA contains one active pharmaceutical ingredient (API):

1	Alogliptin UNII EEN99869SC - ALOGLIPTIN BENZOATE
	Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.
	Read more about Alogliptin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NESINA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BH04		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
Discover more medicines within A10BH04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2933J, 2944Y, 2986E
BR	Câmara de Regulação do Mercado de Medicamentos	501114030021802, 501114030022102, 501114030022302, 501114030022402
CA	Health Products and Food Branch	02417189, 02417197, 02417200
HK	Department of Health Drug Office	63496, 63497, 63498
JP	医薬品医療機器総合機構	3969012F1025, 3969012F2021, 3969012F3028
SG	Health Sciences Authority	14812P, 14813P, 14814P, 14842P, 14843P
US	FDA, National Drug Code	64764-125, 64764-250, 64764-625